42CAP

42CAP is a Munich-based micro-fund built around a tightly defined thesis: data-driven, globally scalable B2B software, with founders evaluated as much on engineering culture as on market opportunity. The firm explicitly favors small, concentrated portfolios over broad diversification, which means partner attention is generally high and selection bar correspondingly steep.

The healthcare thesis is concentrated on health IT software, with a bias toward companies whose product is a clean SaaS or data infrastructure play and whose buyers look like enterprise software customers rather than clinical committees. The firm is more comfortable with horizontal data and software products that happen to apply in healthcare than with deeply regulated clinical or device businesses. Specific healthcare portfolio companies are not enumerated in the source material, so founders should request relevant references during diligence rather than rely on category positioning.

42CAP invests at Pre-Seed and Seed only, with checks of one to five million dollars. That stage discipline is unusual and worth taking at face value: the firm does not lead Series A rounds and does not try to play a multi-stage role. The geographic focus is Europe with a German center of gravity, with an explicit interest in companies built for global scale from inception. For founders, that means 42CAP is most useful as an early lead or significant co-investor at Seed and as a credible signal into later-stage syndicates, but follow-on capacity beyond Seed is not a feature of the relationship.

The team is built around partners with backgrounds in operating and investing in B2B software, with a publicly emphasized engineering and data-centric orientation. Specific partner names are not provided in the source material, so founders should clarify which partner leads health IT and what the diligence process actually involves.

The right founders for 42CAP are data-native B2B software teams building products with credible global reach from day one, where the firm’s pattern recognition is genuinely tuned. The wrong founders are domestically focused, services-heavy, or clinically regulated teams, where the firm’s lens may not produce useful pressure. Founders should expect direct questions about data flywheel design, technical scalability, and international go-to-market, and should be prepared to defend why their company is built for global scale rather than national success. The firm rewards founders who can describe their competitive moat in technical and data terms rather than in narrative ones.